Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Alto Neuroscience, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Alto Neuroscience, Inc. has 12 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Alto Neuroscience, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Alto Neuroscience, Inc.. Customers appear here when Alto Neuroscience, Inc. names them, or when a company names Alto Neuroscience, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For example, we depend on licenses from Sanofi and MedRx for certain intellectual property relating to the development and commercialization of ALTO-101.”
FILING10-K0001999480-26-000002cik 0001999480
“In October 2021, we entered into an asset purchase agreement, or the Teva Agreement, with Teva Pharmaceutical Industries, Ltd. and its affiliate Cephalon, Inc., or, together Teva, pursuant to which we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds, and we assumed all post-acquisition liabilities related thereto.”
FILING10-K0001999480-26-000002cik 0001999480
“In December 2019, we entered into an exclusive license agreement with equity, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, which was subsequently amended in May 2020 and December 2023.”
FILING10-K0001999480-26-000002cik 0001999480
“In May 2025, we entered into an asset purchase agreement, or the Chase Agreement, with Chase Therapeutics Corporation, or Chase, pursuant to which we acquired all patent, know-how and other rights to ALTO-207, ALTO-208, and certain related asset, or the Acquired Chase Compounds.”
FILING10-K0001999480-26-000002cik 0001999480
“In connection with the transactions effected by the Palisade Agreement, Palisade also transferred and assigned to us all right, title, and interest in, to, and under an exclusive license agreement, or the Dow Agreement, between Dow Agrosciences LLC, or Dow, and Palisade (f/k/a Neuralstem, Inc.), dated as of December 1, 2016, as a result of which we obtained an exclusive, sublicensable license under certain patent rights of Dow to make, have made, use, and have used, certain compounds covered by such patent rights and to make, have made, offer for sale, sell, import, and have imported, products using such compounds, including Palisade Acquired Products, for the development, synthesis, and commercialization of such products as prescription human pharmaceutical in the United States.”
FILING10-K0001999480-26-000002cik 0001999480
“For example, we depend on licenses from Sanofi and MedRx for certain intellectual property relating to the development and commercialization of ALTO-101.”
FILING10-K0001999480-26-000002cik 0001999480
“Merck and its affiliates retained a co-exclusive, worldwide right under Merck's patent rights and know-how sublicensed to us by Cerecor to research, make, have made, use and import ALTO-202 and Cerecor Licensed Products solely for non-human, non-commercial purposes, and we received a non-exclusive worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights covering improvements made by Merck through its exercise of such retained right.”
FILING10-K0001999480-26-000002cik 0001999480
“In October 2021, we entered into an asset transfer agreement, or the Palisade Agreement, with Palisade Bio, Inc., or Palisade, pursuant to which we acquired all patent, know-how and other rights to ALTO-100.”
FILING10-K0001999480-26-000002cik 0001999480
“The Convertible Grant Agreement provides for an unsecured convertible loan, or the Convertible Loan, from Wellcome of up to approximately $11.7 million, payable in six tranches.”
FILING10-K0001999480-26-000002cik 0001999480
“The Convertible Grant Agreement provides for the Convertible Loan from Wellcome of up to approximately $11.7 million, payable in six tranches.”
FILING10-K0001999480-26-000002cik 0001999480
“In December 2022, we entered into a loan and security agreement, or the Original Loan Agreement, with K2 HealthVentures, as a lender and the other lenders from time to time party thereto, or collectively, the Lender, K2 HealthVentures, as administrative agent for the Lender, and Ankura Trust Company, LLC, as collateral agent for the Lender.”
FILING10-K0001999480-26-000002cik 0001999480
“In December 2022, we entered into a loan and security agreement, or the Original Loan Agreement, with K2 HealthVentures, as a lender and the other lenders from time to time party thereto, or collectively, the Lender, K2 HealthVentures, as administrative agent for the Lender, and Ankura Trust Company, LLC, as collateral agent for the Lender.”
FILING10-K0001999480-26-000002cik 0001999480
Watchlist prices, news filtered to it, and its next report on your desk.
No intraday reading yet this session.
ANRO (Alto Neuroscience, Inc.) has 12 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.